Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases.

ABSTRACT: Brain metastases cause significant morbidity and mortality in patients with advanced cancer. In the era of precision oncology and immunotherapy, there are rapidly evolving systemic treatment options. These novel therapies may have variable intracranial efficacy, and patients with brain metastases remain a population of special interest. Typically, only patients with stable, asymptomatic and/or treated brain metastases are enrolled in clinical trials, or may be excluded altogether, particularly in the setting of leptomeningeal carcinomatosis. Consequently, this leads to significant concerns on the external validity of clinical trial evidence to real-world clinical practice. Here we describe the current trends in cancer clinical trial eligibility for patients with brain metastases in both ea

SUBMITTER: Tan AC 

PROVIDER: S-EPMC8761732 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature